脂蛋白相关磷脂酶A2与动脉粥样硬化及冠心病关系的研究进展

摘要
图/表
参考文献(30)
相关文章 (15)

全文: PDF (0 KB) HTML (42 KB)
输出: BibTeX | EndNote (RIS)

摘要心血管疾病（CVD）已成为危害人类健康的一种严重疾病，在我国，其发病率、死亡率居高不下，给人们生活带来了极大的痛苦和负担。近年来，随着深入研究动脉粥样硬化及冠心病，脂蛋白相关磷脂酶A2（Lp-PLA2）作为一种新发现的炎症标志物因参与其发生、发展过程而愈发受到人们的关注，现其被认为是CVD 风险的变化性预测因素。经过对近些年相关文献的整理，本文主要综述了Lp-PLA2 结构特性、影响因素及其与动脉粥样硬化及冠心病之间的关系。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李志红1
	2
	申强1
	2

关键词 ：动脉粥样硬化, 冠心病, 粥样斑块, 磷脂酶A2

Abstract：Cardiovascular disease (CVD) has become a serious disease endangering human health,and its morbidity and mortality remain high in China,which brings great pain and burden to people′s lives.In recent years,with the indepth study of atherosclerosis and coronary heart disease,lipoprotein-associated phospholipase A2 (Lp-PLA2),as a newly discovered inflammatory marker,has attracted more and more attention due to its involvement in its occurrence and development,and now it is considered to be a variable predictor of CVD risk.After collating the related literature in recent years,this paper mainly reviews the structural characteristics and influencing factors of Lp-PLA2 and its relationship with atherosclerosis and coronary heart disease.

Key words： Atherosclerosis Coronary heart disease Atherosclerotic plaque Phospholipase A2

通讯作者: 申强（1973-），教授，主要从事心内科常见疾病、疑难危重疾病及介入治疗工作

作者简介: 李志红（1993-），吉首大学医学院2018级在读硕士研究生，主要从事心血管疾病研究

引用本文:

李志红1，2；申强1，2. 脂蛋白相关磷脂酶A2与动脉粥样硬化及冠心病关系的研究进展[J]. 中国当代医药, 2020, 27(31): 21-25.
LI Zhi-Hong1,2；SHEN Qiang1，2▲. Research progress on the relationship between lipoprotein-associated phospholipase A2 and atherosclerosis and coronary heart disease. 中国当代医药, 2020, 27(31): 21-25.

链接本文:

https://www.dangdaiyiyao.com/CN/ 或 https://www.dangdaiyiyao.com/CN/Y2020/V27/I31/21

[1]	Li H，Sun K，Zhao R，et al.Inflammatory biomarkers of coronary heart disease[J].Front Biosci （Schol Ed），2018，10：185-196.
[2]	Tousoulis D，Kampoli A，Papageorgiou N，et al.Pathophysiology of atherosclerosis： the role of inflammation[J].Curr Pharm Des，2011，17（37）：4089-4110.
[3]	Dennis EA，Cao J，Hsu YH，et al.Phospholipase A2 enzymes：physical structure，biological function，disease implication，chemical inhibition，and therapeutic intervention[J].Chem Rev，2011，111（10）：6130-6185.
[4]	Rosenson RS，Stafforini DM.Modulation of oxidative stress，inflammation，and atherosclerosis by lipoprotein-associated phospholipase A2[J].J Lipid Res，2012，53（9）：1767-1782.
[5]	Goncalves I，Edsfeldt A，Ko NY，et al.Evidence supporting a key role of Lp-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation[J].Arterioscler Thromb Vasc Biol，2012，32（6）：1505-1512.
[6]	熊燕华，张大庆.《脂蛋白相关磷脂酶A2 临床应用中国专家建议》解读[J].中国医药导刊，2018，20（3）：138-145.
[7]	Seyedi S，Mottaghi A，Mirmiran P，e t al.The relationship between dietary patterns and lipoprotein-associated phospholipase A2 levels in adults with cardiovascular risk factors：Tehran Lipid and Glucose Study[J].J Res Med Sci，2020，25：3.
[8]	Packard CJ，O′Reilly DS，Caslake MJ，et al.Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease.West of Scotland Coronary Prevention Study Group[J].N Engl J Med，2000，343（16）：1148-1155.
[9]	Ge PC，Chen ZH，Pan RY，et al.Synergistic Effect of Lipoprotein-Associated Phospholipase A2 with Classical Risk Factors on Coronary Heart Disease：A Multi-Ethnic Study in China[J].Cell Physiol Biochem，2016，40（5）：953-968.
[10]	Wang X，Chen Q，Xu Y，et al.Risk factors of atherosclerotic tissue types in single-vessel and intermediate coronary lesions：a cross-sectional study[J].Lipids Health Dis，2017，16（1）：63.
[11]	Wang C，Fang X，Hua Y，et al.Lipoprotein -Associated Phospholipase A2 and Risk of Carotid Atherosclerosis and Cardiovascular Events in Community-Based Older Adults in China[J].Angiology，2018，69（1）：49-58.
[12]	Li D，Zhao L，Yu J，et al.Lipoprotein-associated phospholipase A2 in coronary heart disease：Review and metaanalysis[J].Clin Chim Acta，2017，465：22-29.
[13]	Li D，Wei W，Ran X，et al.Lipoprotein-associated phospholipase A2 and risks of coronary heart disease and ischemic stroke in the general population：A systematic review and meta-analysis[J].Clin Chim Acta，2017，471：38-45.
[14]	Li J，Wang H，Tian J，et al.Change in lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndrome[J].Medicine （Baltimore），2018，97（28）：e11517.
[15]	王凌，谢伟贤，邓爱红.血浆脂蛋白相关磷脂酶A2 水平在冠心病患者严重程度评估中的应用价值[J].慢性病学杂志，2019，20（3）：358-360.
[16]	Lu J，Niu D，Zheng D，et al.Predictive value of combining the level of lipoprotein-associated phospholipase A2 and antithrombin Ⅲfor acute coronary syndrome risk[J].Biomed Rep，2018，9（6）：517-522.
[17]	Yang F，Ma L，Zhang L，et al.Association between serum lipoprotein-associated phospholipase A2，ischemic modified albumin and acute coronary syndrome：a cross-sectional study[J].Heart Vessels，2019，34（10）：1608-1614.
[18]	Yang L，Liu Y，Wang S，et al.Association between Lp-PLA2 and coronary heart disease in Chinese patients[J].J Int Med Res，2017，45（1）：159-169.
[19]	王娜，刘和俊.脂蛋白相关磷脂酶A2与早发冠心病的相关性分析[J].中国实用医药，2020，15（14）：14-16.
[20]	Ma CY，Xu ZY，Wang SP，et al.Change of Inflammatory Factors in Patients with Acute Coronary Syndrome[J].Chin Med J （Engl），2018，131（12）：1444-1449.
[21]	Li J，Zhou Z，Niu X，et al.Lipoprotein-Associated Phospholipase A2 in Cardiac Disease：a Potential Early Biomarker of Unstable Coronary Artery Disease[J].Clin Lab，2020，66（5）.doi：10.7754/Clin.Lab.2019.190719.
[22]	Fleming I，Mohamed A，Galle J，et al.Oxidized low-density lipoprotein increases superoxide production by endothelial nitric oxide synthase by inhibiting PKCalpha[J].Cardiovasc Res，2005，65（4）：897-906.
[23]	Yang L，Cong HL，Wang SF，et al.AMP-activated protein kinase mediates the effects of lipoprotein-associated phospholipase A2 on endothelial dysfunction in atherosclerosis[J].Exp Ther Med，2017，13（4）：1622-1629.
[24]	Wu C，Zhou T，Zhou Y，et al.Association of Serum Lipoprotein-Associated Phospholipase A2 and A379V Gene Polymorphisms with Carotid Plaques[J].Genet Test Mol Biomarkers，2020，24（3）：131-137.
[25]	Heriansyah T，Nafisatuzzamrudah N，Aini FN，et al.Reduction in Vasa Vasorum Angiogenesis by Lp-PLA2 Selective Inhibitor Through The HIF-1α and VEGF Expression Under Dyslipidemic Conditions in Atherosclerosis Pathogenesis[J].Cardiovasc Hematol Agents Med Chem，2018，16（2）：114-119.
[26]	Johnson JL，Shi Y，Snipes R，et al.Effect of darapladib treatment on endarterectomy carotid plaque lipoproteinassociated phospholipase A2 activity：a randomized，controlled trial[J].PLoS One，2014，9（2）：e89034.
[27]	Prasad M，Lennon R，Barsness GW，et al.Chronic inhibition of lipoprotein-associated phospholipase A2 does not improve coronary endothelial function：A prospective，randomized-controlled trial[J].Int J Cardiol，2018，253：7-13.
[28]	Kokotou MG，Limnios D，Nikolaou A，et al.Inhibitors of phospholipase A2 and their therapeutic potential：an update on patents （2012-2016）[J].Expert Opin Ther Pat，2017，27（2）：217-225.
[29]	Santoso A，Heriansyah T，Rohman MS.Phospholipase A2 is an Inflammatory Predictor in Cardiovascular Diseases：Is there any Spacious Room to Prove the Causation?[J].Curr Cardiol Rev，2020，16（1）：3-10.
[30]	Maiolino G，Bisogni V，Rossitto G，et al.Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications[J].World J Cardiol，2015，7（10）：609-620.